低血压对急性心力衰竭预后的影响
Hyun-Jin Kim1, Sang-Ho Jo2,3
1Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Guri Hospital, Guri, Korea.
Scientific reports
|July 6, 2024
概括
心力衰竭患者的低血压与减少喷射率 (HFrEF) 患者的低血压与更糟糕的结果有关. 对于心力衰竭与轻微减少/保留射出分数 (HFmrEF/HFpEF),初始血压没有显著影响临床结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 低血压 (BP) 是心力衰竭 (HF) 患者不良结果的已知预测因素.
- 了解初始血压对高血压预后和药物治疗模式的影响对于优化患者护理至关重要.
研究的目的:
- 研究初始血压对急性HF患者预后的影响.
- 根据最初的BP. 检查基于HF药物的处方模式.
- 根据血压,区分心力衰竭与减少喷射率 (HFrEF) 和心力衰竭轻度减少/保留喷射率 (HFmrEF/HFpEF) 之间的结果.
主要方法:
- 对2778名急性HF入院患者的多中心队列的分析.
- 将患者分为HFrEF和HFmrEF/HFpEF组进行分类.
- 将初始心压和心压血压分类为特定范围,以评估结果和药物使用 (ACEi,ARB,BB).
主要成果:
- 在HFrEF患者中,较低的初始血压与增加的全因死亡和复合临床事件相关.
- 初始静脉血压<120 mmHg和静脉血压<80 mmHg独立地与HFrEF的长期死亡率显著增加有关.
- 在HFrEF患者中,ACEi,ARB或BB的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在ACEi,ARB或BB的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用在HFrEF患者的使用
- 根据初始血压水平,在HFmrEF/HFpEF患者中没有观察到临床结果的显著差异.
结论:
- 在HFrEF患者中,初始低血压是不良临床结果和死亡率增加的重要预测因素.
- 在HFmrEF/HFpEF患者中没有观察到初始低血压的预后意义.
- 调查结果强调了在HFrEF的风险分层和管理策略中考虑初始BP的重要性.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:17Measurement of Blood Pressure
907
Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
907
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:30Alterations in Blood Pressure
1.2K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419